(4S)-3-[(2R)-2-[(2R)-2-(2,4-Difluorophenyl)oxiranyl]-1-oxopropyl]-4-benzyl-2-oxazolidinone-d3

(4S)-3-[(2R)-2-[(2R)-2-(2,4-Difluorophenyl)oxiranyl]-1-oxopropyl]-4-benzyl-2-oxazolidinone-d3 is a deuterated form of the drug linezolid, which is used to treat bacterial infections. This compound has been labeled with deuterium, a stable isotope of hydrogen, for use in research and development. Linezolid works by inhibiting the synthesis of bacterial proteins, which prevents the bacteria from growing and multiplying. This compound is effective against a wide range of bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE). The addition of deuterium to (4S)-3-[(2R)-2-[(2R)-2-(2,4-Difluorophenyl)oxiranyl]-1-oxopropyl]-4-benzyl-2-oxazolidinone-d3 allows for better understanding of the pharmacokinetics and metabolism of linezolid in the body. Deuterium labeling is a common technique used in pharmaceutical research to track the fate of drugs in the body and to optimize drug dosing. Overall, (4S)-3-[(2R)-2-[(2R)-2-(2,4-Difluorophenyl)oxiranyl]-1-oxopropyl]-4-benzyl-2-oxazolidinone-d3 is a valuable tool for researchers in the field of drug development and may ultimately lead to the discovery of new and more effective treatments for bacterial infections.